This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific meetings of the summer.

First, we discuss Vertex’s $10 billion acquisition of Crinetics Pharmaceuticals, the company’s largest deal to date, and what it says about Vertex’s push beyond its historic strength in cystic fibrosis. We also cover growing scrutiny from U.S. lawmakers over the industry’s use of clinical trials in China.

Then, Fierce Pharma Senior Editor Fraiser Kansteiner recounts his recent trip to New Orleans for the American Diabetes Association’s 2026 Scientific Sessions with Fierce Pharma Marketing’s Zoey Becker. For years, ADA has focused heavily on its eponymous indication, but this year’s meeting made clear how much the conversation is evolving, with obesity data from drugmakers of all stripes taking up more of the spotlight. Topics include the biggest data sets from the meeting, what it was like to sit down with Novo Nordisk’s new CEO for the first time and the latest from Insulet’s Marvel collaboration on a line of comics about an Omnipod-wearing superheroine.

To learn more about the topics in this episode:

• Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B
• As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’
• ‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO
• ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes
• ADA: Amgen highlights Repatha perks, GLP-1 pitfalls in push to boost cardiometabolic pedigree
• With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race
• ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone
• ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect
• ADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update
• ADA: Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetes

See omnystudio.com/listener for privacy information.

AI is reshaping how organizations compete, but more data and more tools do not automatically lead to better decisions. In this episode of The Top Line, Justin Masterson, senior vice president of human sciences at The Directions Group, challenges leaders to look beyond AI adoption and focus on the discipline required to act on intelligence.

Masterson argues that the defining issue for many organizations is not a data problem, but a decision readiness problem. As information ecosystems become more complex, the ability to translate insight into timely, confident action is emerging as a critical business differentiator.

With more than 20 years of experience in healthcare and human sciences, Masterson shares perspective on how companies can align teams, processes and strategies to unlock AI’s value without becoming overwhelmed by the volume of available information.

For leaders navigating new technologies, competing priorities and higher expectations for speed, this conversation offers a practical reframing of where AI value is created. Learn why decision readiness may be the next true advantage.

See omnystudio.com/listener for privacy information.

Big Pharma dealmaking has picked up, but the biotech path to a signed agreement is still anything but simple.

In this episode, recorded at Fierce Biotech Week, Senior Editor James Waldron leads a discussion on the evolving BD&L landscape across pharma and biotech.

He is joined by Kaleem Chowdhury, Ph.D., CEO of Haiku Biosciences; Liz Leveille, who leads the Boston Innovation Hub and discovery transactions at Merck; and Abbas Kazemi, CEO of Nimbus Therapeutics.

The panel digs into the realities behind the headlines, from investor scrutiny and platform company pressure to China’s growing role in licensing and the long relationship-building that often happens before a deal gets done.

To learn more about the topics in this episode:

• March M&A surge triggers high expectations for 2026
• 'Biopharma ecosystem is back to full health,' fueled by M&A: PwC
• Facing mounting China licensing costs, biopharma buyers turn to AI and local know-how to keep up
• After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst
• Was Big Pharma’s ‘unusually aggressive’ M&A spree to blame for March IPO drought?

This week's episode is sponsored by IQVIA Biotech.

Built for biotech innovators, IQVIA Biotech is a full-service CRO, designed for agility, fast decisions, and the urgency needed for emerging biopharma. With dedicated teams and deep therapeutic expertise, we help move programs forward with focus and confidence. Visit IQVIABiotech.com

See omnystudio.com/listener for privacy information.